The risks of converting post-hoc findings into primary outcomes in subsequent trials.
作者信息
Rodrigues Filipe B, Ferreira Joaquim J
机构信息
UCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S337. doi: 10.21037/atm.2019.09.105.
Abstract
摘要
相似文献
1
The risks of converting post-hoc findings into primary outcomes in subsequent trials.
Ann Transl Med. 2019 Dec;7(Suppl 8):S337. doi: 10.21037/atm.2019.09.105.
2
Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline.
Ann Intern Med. 2012 Apr 17;156(8):570-81. doi: 10.7326/0003-4819-156-8-201204170-00004.
3
Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four Analyses of Randomized Clinical Trials.
Front Cardiovasc Med. 2022 Mar 4;9:841341. doi: 10.3389/fcvm.2022.841341. eCollection 2022.
4
Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials.
J Alzheimers Dis. 2016;50(4):1205-15. doi: 10.3233/JAD-150847.
5
The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial.
Ther Adv Cardiovasc Dis. 2018 Dec;12(12):351-359. doi: 10.1177/1753944718809266. Epub 2018 Nov 15.
6
Why caution is recommended with post-hoc individual patient matching for estimation of treatment effect in parallel-group randomized controlled trials: the case of acute stroke trials.
Stat Med. 2013 Nov 10;32(25):4467-81. doi: 10.1002/sim.5862. Epub 2013 Jun 12.
7
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15.
8
Patterns of Antifungal Resistance in Adult Patients With Fungal Keratitis in South India: A Post Hoc Analysis of 3 Randomized Clinical Trials.
JAMA Ophthalmol. 2022 Feb 1;140(2):179-184. doi: 10.1001/jamaophthalmol.2021.5765.
9
The post hoc use of randomised controlled trials to explore drug associated cancer outcomes: methodological challenges.
Curr Drug Saf. 2013 Nov;8(5):371-8. doi: 10.2174/15748863113086660070.
10
Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis.
J Am Coll Cardiol. 2010 May 25;55(21):2299-307. doi: 10.1016/j.jacc.2010.01.043.
本文引用的文献
1
A manifesto for reproducible science.
Nat Hum Behav. 2017 Jan 10;1(1):0021. doi: 10.1038/s41562-016-0021.
2
Huntington's Disease Clinical Trials Corner: June 2019.
J Huntingtons Dis. 2019;8(3):363-371. doi: 10.3233/JHD-199003.
3
International Guidelines for the Treatment of Huntington's Disease.
Front Neurol. 2019 Jul 3;10:710. doi: 10.3389/fneur.2019.00710. eCollection 2019.
4
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15.
5
Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort.
Mov Disord Clin Pract. 2017 May 26;4(5):737-742. doi: 10.1002/mdc3.12502. eCollection 2017 Sep-Oct.
6
Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.
Mov Disord Clin Pract. 2018 May 9;5(4):361-372. doi: 10.1002/mdc3.12617. eCollection 2018 Jul-Aug.
7
Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease.
Mov Disord Clin Pract. 2016 Jun 22;4(2):212-224. doi: 10.1002/mdc3.12388. eCollection 2017 Mar-Apr.
8
Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.
Mov Disord Clin Pract. 2018 Jan 3;5(2):111-117. doi: 10.1002/mdc3.12571. eCollection 2018 Mar-Apr.
9
Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
Sci Transl Med. 2018 Sep 12;10(458). doi: 10.1126/scitranslmed.aat7108.
10
Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life.
Mov Disord. 2018 May;33(5):742-749. doi: 10.1002/mds.27317. Epub 2018 Mar 23.
Zotero 插件